Privacy Policy
Signals Blog

Contributors

Categories

How does the U.S. public rate the FDA’s performance?

. The U.S. Food and Drug Administration’s (FDA) ongoing efforts to assert its authority to regulate U.S.-based companies that offer unlicensed stem cell therapies (Regenerative Sciences or Celltex, for example) has prompted a mixed response from the regenerative...

Right Turn: Primer on MSCs in clinical trials

. In this podcast titled “Opportunities and Challenges in Developing Innovative Stem Cell Therapies,” Dr. Armand Keating focuses specifically on the commercialization of mesenchymal stem cells (stromal cells). He has established the largest stem cell transplant...

Right Turn: Biting into some incredible art

Developmental biologists among you may be aware that voting in the Node’s image competition wrapped this week. Five wonderful images were in the running for the cover on a future issue of Development – and bragging rights, of course. I discovered the...

Right Turn: Research at the bleeding edge. Literally.

How many university students can say they invented a product that people around the world will want to use? For that matter, how many people have ever invented a product that made it to the market?! Joe Landolina is CEO and Co-Founder of Suneris, Inc. and a student at...

Subscribe to Signals

Subscribe to our blog list to receive the latest news and updates.

You have Successfully Subscribed!